{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:12:25Z","timestamp":1759011145424,"version":"3.44.0"},"reference-count":7,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jinf.2022.07.004","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T01:37:32Z","timestamp":1657244252000},"page":"e94-e95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["High efficacy of glecaprevir\/pibrentasvir for HCV-infected individuals with active drug use: Some issues"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2296-3054","authenticated-orcid":false,"given":"Chia-Yen","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee-Fu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2022.07.004_bib0001","unstructured":"Gonz\u00e1lez-Serna A., Macias J., Corma-Gomez A., Tellez F., Cucurull J., Real L.M., et\u00a0al. High efficacy of Glecaprevir\/Pibrentasvir for HCV-Infected individuals with active drug use. J Infect 2022:S0163-4453(22)00358-9 (in press)."},{"key":"10.1016\/j.jinf.2022.07.004_bib0002","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/liv.14849","article-title":"Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: a real-world nationwide hepatitis C virus registry programme in Taiwan","volume":"41","author":"Chen","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jinf.2022.07.004_bib0003","unstructured":"Taiwan Centers for Disease Control. Press release., 2020, https:\/\/www.cdc.gov.tw\/En."},{"key":"10.1016\/j.jinf.2022.07.004_bib0004","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jinf.2020.08.007","article-title":"The strategies for the coronavirus disease 2019 (COVID-19) in Taiwan: a different tale","volume":"82","author":"Dai","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2022.07.004_bib0005","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/liv.14412","article-title":"Taiwan is on track of accelerating hepatitis C elimination by 2025","volume":"40","author":"Wu","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jinf.2022.07.004_bib0006","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3350\/cmh.2020.0150","article-title":"Scaling up the in-hospital hepatitis C virus care cascade in Taiwan","volume":"27","author":"Huang","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jinf.2022.07.004_bib0007","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jfma.2020.04.002","article-title":"2020 Taiwan consensus statement on the management of hepatitis C: part (II) special populations","volume":"119","author":"Yu","year":"2020","journal-title":"J Formos Med Assoc"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445322004091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445322004091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:36:16Z","timestamp":1759008976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445322004091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0163445322004091"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2022.07.004","relation":{},"ISSN":["0163-4453"],"issn-type":[{"type":"print","value":"0163-4453"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High efficacy of glecaprevir\/pibrentasvir for HCV-infected individuals with active drug use: Some issues","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2022.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}]}}